An Update on the Incidence, Risk Factors and Mechanisms of Rituximab-associated Neutropenia

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2024 May 17

PMID 38757021

Authors

Xuehan Zhang

Meiying Rao

Gaosi Xu

Affiliations

Soon will be listed here.

Abstract

With the increasing application of rituximab (RTB) in hematological diseases and autoimmune diseases (AIDs), we have gradually increased our awareness of the adverse reaction of rituximab-associated neutropenia (RAN), but little is known about its true incidence rate, susceptibility risk factors and exact pathogenesis. At present, research groups have conducted a large number of studies on different populations. The team found that age (> 60), advanced disease, systemic lupus erythematosus (SLE) and combined cyclophosphamide therapy were independent risk factors for RAN. However, its exact mechanism is not completely clear. Several hypotheses have been put forward to solve this question, including the production of anti-neutrophil antibodies after RTB, the generation disorder and neutrophil maturation stagnation caused by abnormal B-cell reconstruction, and the amplification of T-large granular lymphocyte population that may induce neutrophil apoptosis. However, there are still many unsolved problems in all aspects of RAN. This article is an update of the incidence rate, risk factors and mechanisms of RAN.

Citing Articles

Late-onset Neutropenia after Rituximab Treatment for MPO-ANCA-associated Vasculitis.

Watanabe K, Shimada N, Kanzaki M, Fukuoka K, Asano K Intern Med. 2024; 64(4):581-584.

PMID: 39019601 PMC: 11904456. DOI: 10.2169/internalmedicine.3357-23.

References

Stamatopoulos K, Papadaki T, Pontikoglou C, Athanasiadou I, Stavroyianni N, Bux J . Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia. 2008; 22(7):1446-9. DOI: 10.1038/sj.leu.2405077. View

Parodis I, Soder F, Faustini F, Kasza Z, Samuelsson I, Zickert A . Rituximab-mediated late-onset neutropenia in systemic lupus erythematosus - distinct roles of BAFF and APRIL. Lupus. 2018; 27(9):1470-1478. DOI: 10.1177/0961203318777116. View

Cattaneo C, Spedini P, Casari S, Re A, Tucci A, Borlenghi E . Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. Leuk Lymphoma. 2006; 47(6):1013-7. DOI: 10.1080/10428190500473113. View

Fukuno K, Tsurumi H, Ando N, Kanemura N, Goto H, Tanabashi S . Late-onset neutropenia in patients treated with rituximab for non-Hodgkin's lymphoma. Int J Hematol. 2006; 84(3):242-7. DOI: 10.1532/IJH97.05105. View

Ma Q, Jones D, Springer T . The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity. 1999; 10(4):463-71. DOI: 10.1016/s1074-7613(00)80046-1. View

Villalba S, Salvucci O, Aoki Y, De La Luz Sierra M, Gupta G, Davis D . Serum inactivation contributes to the failure of stromal-derived factor-1 to block HIV-I infection in vivo. J Leukoc Biol. 2003; 74(5):880-8. DOI: 10.1189/jlb.0403149. View

Abdulkader R, Dharmapalaiah C, Rose G, Shand L, Clunie G, Watts R . Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol. 2014; 41(5):858-61. DOI: 10.3899/jrheum.130526. View

Mealy M, Levy M . Favorable outcome of granulocyte colony-stimulating factor use in neuromyelitis optica patients presenting with agranulocytosis in the setting of rituximab. J Neuroimmunol. 2015; 287:29-30. PMC: 4795454. DOI: 10.1016/j.jneuroim.2015.08.003. View

Miller J, Stadanlick J, Cancro M . Space, selection, and surveillance: setting boundaries with BLyS. J Immunol. 2006; 176(11):6405-10. DOI: 10.4049/jimmunol.176.11.6405. View

10.

Liu J, Wei S, Lamy T, Epling-Burnette P, Starkebaum G, Djeu J . Chronic neutropenia mediated by fas ligand. Blood. 2000; 95(10):3219-22. View

11.

Egawa T, Kawabata K, Kawamoto H, Amada K, Okamoto R, Fujii N . The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor. Immunity. 2001; 15(2):323-34. DOI: 10.1016/s1074-7613(01)00185-6. View

12.

Ceradini D, Kulkarni A, Callaghan M, Tepper O, Bastidas N, Kleinman M . Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med. 2004; 10(8):858-64. DOI: 10.1038/nm1075. View

13.

Sebastiani M, Anelli M, Atzeni F, Bazzani C, Farina I, Fedele A . Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. Joint Bone Spine. 2014; 81(6):508-12. DOI: 10.1016/j.jbspin.2014.06.011. View

14.

Wolach O, Bairey O, Lahav M . Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore). 2010; 89(5):308-318. DOI: 10.1097/MD.0b013e3181f2caef. View

15.

Otrock Z, Mahfouz R, Oghlakian G, Salem Z, Bazarbachi A . Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica. 2005; 90 Suppl:ECR23. View

16.

Bleul C, Fuhlbrigge R, Casasnovas J, Aiuti A, Springer T . A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med. 1996; 184(3):1101-9. PMC: 2192798. DOI: 10.1084/jem.184.3.1101. View

17.

Cambridge G, Stohl W, Leandro M, Migone T, Hilbert D, Edwards J . Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006; 54(3):723-32. DOI: 10.1002/art.21650. View

18.

Arroyo-Avila M, Fred-Jimenez R, Vila L . Early-onset neutropenia induced by rituximab in a patient with lupus nephritis and hemolytic anemia. Case Rep Rheumatol. 2015; 2015:616787. PMC: 4342062. DOI: 10.1155/2015/616787. View

19.

Danes I, Agusti A, Vallano A, Martinez J, Alerany C, Ferrer A . Available evidence and outcome of off-label use of rituximab in clinical practice. Eur J Clin Pharmacol. 2013; 69(9):1689-99. DOI: 10.1007/s00228-013-1518-4. View

20.

Dunleavy K, Hakim F, Kim H, Janik J, Grant N, Nakayama T . B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood. 2005; 106(3):795-802. PMC: 1895166. DOI: 10.1182/blood-2004-08-3198. View